bioRxivPhysiology
The mechanism underlying transient weakness in myotonia congenita
M. M. Rich, J. H. Myers, K. Denman, C. DuPont, A. A. Hawash, K. R. Novak, A. Koesters, M. Grabner, A. Dayal, A. A. Voss
Abstract
In addition to the hallmark muscle stiffness, patients with recessive myotonia congenita (Becker disease) experience debilitating bouts of transient weakness that remain poorly understood despite years of study. We made intracellular recordings from muscle of both genetic and pharmacologic mouse models of Becker disease to identify the mechanism underlying transient weakness. Our recordings reveal transient depolarizations (plateau potentials) of the membrane potential to -25 to -35 mV in the genetic and pharmacologic models of Becker disease. Both Na+ and Ca2+ currents contribute to plateau potentials. Na+ persistent inward current (NaPIC) through Na{gamma}1.4 channels is the key trigger of plateau potentials and current through Cav1.1 Ca2+ channels contributes to the duration of the plateau. Inhibiting NaPIC with ranolazine prevents the development of plateau potentials and eliminates transient weakness in vivo. These data suggest that targeting NaPIC may be an effective treatment to prevent transient weakness in myotonia congenita. Impact StatementTransient weakness in myotonia congenita is caused by depolarization secondary to activation of persistent Na+ current in skeletal muscle.
- organism: mouse
- assay: electrophysiology
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Myotonic Muscle Activity Drives a Persistent Pain State Responsive to NaV1.8-directed Analgesics
Tyler S. Nelson, Aida Calderón‐Rivera, … Rajesh Khanna·Journal of Clinical InvestigationPeer-reviewed·Sep 8, 2026
- Voltage-Dependent Ca2+ Release Is Impaired in Hypokalemic Periodic Paralysis Caused by CaV1.1-R528H but not by NaV1.4-R669H
M. DIFRANCO, S. C. Cannon·bioRxiv·May 17, 2022
- The Role of Action Potential Waveform in Failure of Excitation Contraction Coupling
X. Wang, M. Nawaz, … M. M. Rich·bioRxiv·Jun 29, 2021
- Retigabine Suppresses Loss of Force in a Mouse Model of Hypokalemic Periodic Paralysis
M. Quinonez, S. C. Cannon·bioRxiv·May 20, 2022
- A Mixed Periodic Paralysis & Myotonia Mutant, P1158S, Imparts pH Sensitivity in Skeletal Muscle Voltage-gated Sodium Channels
M.-R. Ghovanloo, M. Abdelsayed, … P. C. Ruben·bioRxiv·Jul 17, 2017
- The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels
Jakob Sauer, Jessica Marksteiner, … Oliver Kudlacek·American Journal of Physiology-Heart and Circulatory PhysiologyPeer-reviewed·Aug 13, 2025